Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX versus METHADOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX versus METHADOSE.
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX vs METHADOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; chlorpheniramine is a histamine H1 receptor antagonist.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
5 mL (hydrocodone 10 mg/chlorpheniramine 8 mg) orally every 12 hours; maximum 10 mL (20 mg hydrocodone/16 mg chlorpheniramine) per 24 hours.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
None Documented
None Documented
Hydrocodone: 3.8-6 hours (extended-release formulation may have biphasic elimination). Chlorpheniramine: 21-27 hours. Clinical context: Steady-state reached in 2-5 days for chlorpheniramine.
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Renal excretion: hydrocodone primarily as conjugates and unchanged drug (~60%), chlorpheniramine primarily as metabolites (~80% renal). Fecal excretion: minimal (<10%).
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Category D/X
Category C
Opioid Agonist
Opioid Agonist